Safety and Effectiveness of Brigatinib in Anaplastic Lymphoma Kinase (ALK) Positive Metastatic Non-Small Cell Lung Cancer (NSCLC) in Argentina: A Post-Marketing Surveillance Study
Safety and Effectiveness of Brigatinib in Anaplastic Lymphoma Kinase (ALK) Positive Metastatic Non-Small Cell Lung Cancer (NSCLC) in Argentina: A Post-Marketing Surveillance Study
Patricio Levit, Patricio Servienti, Ane Zumárraga, Jose Zarba et al.
Citations
1 citations
Journal
Drugs - Real World Outcomes
Topics
Lung Cancer Treatments and Mutations
Field-Weighted Citation Impact (FWCI)
1.52
article
Safety and Effectiveness of Brigatinib in Anaplastic Lymphoma Kinase (ALK) Positive Metastatic Non-Small Cell Lung Cancer (NSCLC) in Argentina: A Post-Marketing Surveillance Study
Patricio Levit, Patricio Servienti, Ane Zumárraga, Jose Zarba, Gabriela Malcervelli, Vanesa Paola Patronella, Gastón Lucas Martinengo, Laura Brion, Claudio Martín, Elisa Malaver
article en
1 citations
Abstract
No abstract available for this paper.
Publication Tag
Drugs - Real World OutcomesVol. 12(2)
Institutions
Instituto Alexander Fleming (AR), Helios Salud (AR), Instituto de Oncología de Rosario (AR), Hospital General de Agudos Dr. TEODORO ALVAREZ (AR), Takeda (Japan) (JP)